ApoB
Counts the particles. Two people with the same LDL-C can carry it in very different numbers of particles.
Free
Plaque builds while you feel fine. Lower your LDL-C now to slow it.
How would you like to start?
Which medicine fits what matters to you? Pick any.
Watch the needle swing to the best fit. It mirrors your choices; talk the result over with your clinician.
5 scenes · about 2 minutes
1 · Today
Each particle carries one apoB protein, so apoB counts the particles. The more particles in your blood, the more get stuck.
People born with genes that keep LDL-C about 39 mg/dL lower all their lives have about half the risk of heart disease. Source: Ference et al., J Am Coll Cardiol 2012
Tap or scroll for the next scene
Lowering LDL-C slows every step you just saw.
Here's how, in order: your own numbers, then food and exercise, then medicines one step at a time.
Your numbers
Of 100 people like you, about 10 have a heart attack or stroke in the next 10 years.
For an LDL-C of 160 and middle risk ·
Trial averages. Your own result can differ. See the details
Next: why it mattersWhy it matters
Stay at 160 Lower to 70 now Your years so far LDL-C of 100 all along
At 160, you'd reach that level around age 46. Lowering to 70 now pushes that to about 48.
From today on, your total would build up 56% slower.
Using an example LDL-C of 160. The running total is LDL-C times years. It assumes LDL-C of about 100 as a child, then today's level from age 20 on. The band is about 6,200 mg/dL-years (160 mmol/L-years), where heart disease tends to appear (European Atherosclerosis Society, Nordestgaard et al., Eur Heart J 2013). An illustration of the idea. Your own arteries can differ.
Want more data first?
Counts the particles. Two people with the same LDL-C can carry it in very different numbers of particles.
An extra-sticky particle set by your genes. Test it once.
About 1 in 5 people are above this line. Genes set most of it, so one test in adulthood is usually enough.
Shows calcium in plaque that has already formed. It can move your risk estimate up or down.
What's really in the wall: soft plaque, with calcium in some of it.
Only calcium shows. Soft plaque is invisible, so a score of 0 lowers risk but doesn't rule out plaque.
Some calcified plaque. Plaque is present, which often tips the balance toward treatment to lower LDL.
Food first
Now
With these changes
Pick a change to see what it does.
A day of eating
What this looks like on a plate
This day delivers about 8 g of soluble fiber and 2 g of plant sterols, and swaps butter and pastries for olive oil and nuts.
Medicines, step by step
Example
Step 1
atorvastatin, rosuvastatin and others, generic · Pill, daily
Source: Cholesterol Treatment Trialists' (CTT) Collaboration, Lancet 2010
Step 2
Zetia, generic · Pill, daily
Source: Cannon et al., IMPROVE-IT, NEJM 2015
Step 3
evolocumab, alirocumab (Repatha, Praluent) · Shot every 2 or 4 weeks
Source: Sabatine et al., FOURIER, NEJM 2017; Schwartz et al., ODYSSEY OUTCOMES, NEJM 2018; Nicholls et al., GLAGOV, JAMA 2016
Some people can't take a step, or would rather take it another way. These can stand in.
Can't take a statin? It can stand in at step 1, or add on.
Pill, daily
Lowers LDL-C about 17 to 23%
CLEAR Outcomes: 13,970 people who couldn't take a statin. 13% fewer major heart and stroke events, 23% fewer heart attacks. Deaths didn't differ.
Source: Nissen et al., CLEAR Outcomes, NEJM 2023
Another way to lower PCSK9 at step 3, with fewer shots.
Shot at a clinic: day 0, month 3, then every 6 months
Lowers LDL-C about 50%
Outcome trials (ORION-4, VICTORION-2 PREVENT) hadn't reported as of October 2026.
Source: Ray et al., ORION-10 and ORION-11, NEJM 2020
A monthly PCSK9 shot at step 3.
Shot once a month
Lowers LDL-C about 56% more than placebo at one year
Newer, with less long-term outcome data so far.
Source: LIBerate-HR trial, presented ACC 2024
A daily PCSK9 pill at step 3.
Pill, daily, fasting
Lowers LDL-C about 56 to 59% more than placebo
Approved July 2026. Its outcome trial is still running.
Source: CORALreef Lipids and CORALreef HeFH trials
Safety
What monitoring looks like: a lipid panel about 4 to 12 weeks after starting or changing a dose, then every 3 to 12 months. Liver enzymes only if your clinician thinks they're needed.
lipid.site · Your take-home cardSample
Options I tried on
Questions for my clinician
Yours fills in as you go.
The full card adds what you learned, what matters to you, and questions picked for your numbers. Print it. Your browser makes it, with no name on it.
Already on treatment? Track your numbers or share what happened.